NuGen Announces Canada-Wide Launch of InsuJet
NuGen Medical Devices has launched InsuJet™, its needle-free therapeutic administration device, across Canada. The company received orders for 3,250 InsuJet™ starter kits and consumables, generating revenue of $670,000 with a gross margin of $368,500 in Q3 and Q4 2024. The launch began on November 15, coinciding with World Diabetes Day celebrations at Banting House in London, Ontario. Major pharmacy networks including London Drugs, Pharmasave, and others will distribute InsuJet™ through distributors like McKesson Canada and UniPharm, making it accessible to all 12,000 pharmacies across Canada. InsuJet™ is currently approved in 42 countries.
NuGen Medical Devices ha lanciato InsuJet™, il suo dispositivo per l'amministrazione terapeutica senza ago, in tutto il Canada. L'azienda ha ricevuto ordini per 3.250 kit di avviamento InsuJet™ e consumabili, generando un fatturato di $670.000 con un margine lordo di $368.500 nei Q3 e Q4 del 2024. Il lancio è iniziato il 15 novembre, in coincidenza con le celebrazioni per la Giornata Mondiale del Diabete presso la Banting House di Londra, Ontario. Le principali reti di farmacia, tra cui London Drugs, Pharmasave e altre, distribuiranno InsuJet™ attraverso distributori come McKesson Canada e UniPharm, rendendolo accessibile a tutte le 12.000 farmacie in Canada. Attualmente, InsuJet™ è approvato in 42 paesi.
NuGen Medical Devices ha lanzado InsuJet™, su dispositivo de administración terapéutica sin agujas, en todo Canadá. La empresa ha recibido pedidos de 3,250 kits de inicio de InsuJet™ y consumibles, generando ingresos de $670,000 con un margen bruto de $368,500 en el tercer y cuarto trimestre de 2024. El lanzamiento comenzó el 15 de noviembre, coincidiendo con las celebraciones del Día Mundial de la Diabetes en la Casa Banting en Londres, Ontario. Las principales redes de farmacias, incluyendo London Drugs, Pharmasave y otras, distribuirán InsuJet™ a través de distribuidores como McKesson Canada y UniPharm, haciéndolo accesible a las 12,000 farmacias en todo Canadá. Actualmente, InsuJet™ está aprobado en 42 países.
NuGen Medical Devices가 캐나다 전역에 걸쳐 바늘 없는 치료제 투여 장치인 InsuJet™을 출시했습니다. 이 회사는 3,250개의 InsuJet™ 스타터 키트와 소모품에 대한 주문을 받아 $670,000의 수익을 창출했으며, 총 매출은 $368,500에 이릅니다. 출시일은 11월 15일로, 온타리오주 런던의 밴팅 하우스에서 열린 세계 당뇨병의 날 기념행사와 겹쳤습니다. London Drugs, Pharmasave 등 주요 약국 네트워크는 McKesson Canada 및 UniPharm과 같은 유통업체를 통해 InsuJet™을 배급하여, 캐나다의 12,000개 약국에서 접근할 수 있도록 합니다. InsuJet™은 현재 42개국에서 승인을 받았습니다.
NuGen Medical Devices a lancé InsuJet™, son dispositif d'administration thérapeutique sans aiguille, à travers le Canada. L'entreprise a reçu des commandes pour 3 250 kits de démarrage InsuJet™ et des consommables, générant un revenu de $670,000 avec une marge brute de $368,500 au troisième et quatrième trimestre 2024. Le lancement a commencé le 15 novembre, coïncidant avec les célébrations de la Journée mondiale du diabète à la Maison Banting à Londres, Ontario. Des réseaux de pharmacies majeurs, y compris London Drugs, Pharmasave et d'autres, distribueront InsuJet™ par le biais de distributeurs tels que McKesson Canada et UniPharm, le rendant accessible à toutes les 12 000 pharmacies à travers le Canada. InsuJet™ est actuellement approuvé dans 42 pays.
NuGen Medical Devices hat InsuJet™, sein nadelfreies therapeutisches Verabreichungsgerät, in ganz Kanada eingeführt. Das Unternehmen erhielt Bestellungen für 3.250 InsuJet™-Starterkits und Verbrauchsmaterialien, was einen Umsatz von $670.000 und eine Bruttomarge von $368.500 im 3. und 4. Quartal 2024 generierte. Der Launch begann am 15. November, zeitgleich mit den Feierlichkeiten zum Welt-Diabetes-Tag im Banting House in London, Ontario. Große Apothekennetzwerke, einschließlich London Drugs, Pharmasave und anderer, werden InsuJet™ über Großhändler wie McKesson Canada und UniPharm vertreiben, um es in allen 12.000 Apotheken in Kanada zugänglich zu machen. InsuJet™ ist derzeit in 42 Ländern zugelassen.
- Secured orders worth $670,000 with $368,500 gross margin
- Nationwide distribution network reaching 12,000 pharmacies
- Product approved in 42 countries indicating strong market potential
- Partnerships with major pharmacy chains and distributors
- None.
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across Canada
Toronto, Ontario--(Newsfile Corp. - November 22, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce the national launch of InsuJet™ in Canada. The launch began on November 15, in conjunction with the commemoration of the World Diabetes Day, where InsuJet™ was celebrated and recognized at a special event held at Banting House in London, Ontario - the birthplace of Insulin.
NuGen received an initial order for 2,500 and a second order of 750 units of InsuJet™ starter kits and consumables representing revenue of
Leading pharmacy networks such as London Drugs, Prue Integrative Pharmacies, Pharmasave, Wholehealth Pharmacy Partners, Pharma Brands Canada, Overwaite SaveOn Pharmacies and other well-known Canadian pharmacies are supplied with the InsuJet™ through major distributors including McKesson Canada, Khol & Frisch Distributors, Imperial Distributors and UniPharm Distribution, which are collectively providing all 12,000 pharmacies across Canada access to InsuJet™.
Karen Dunlap, NuGen's Interim Chief Executive Officer, commented: "We are extremely excited to be taking NuGen to a new level of distribution globally to manage diabetes and the delivery of insulin needle-free. As the birthplace of Insulin, Canada represents another great place for us with the rest of the world to follow with InsuJet™ approved for use in 42 countries. We are combining our technical IP experience with our distributor's commercial and clinical strategies to support this strong growth."
About NuGen
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously. The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.
For further information, please visit:
Websites: www.insujet.com, and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/
For further information, please contact:
Karen Dunlap, Interim Chief Executive Officer
(404) 386-0955
kdunlap@nugenmd.com
To arrange a media interview with NuGen, please contact:
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231021
FAQ
What is the revenue expected from NuGen's (NGMDF) recent InsuJet orders in Canada?
How many pharmacies will have access to InsuJet through NuGen's (NGMDF) distribution network?
When did NuGen (NGMDF) launch InsuJet in Canada?
In how many countries is NuGen's (NGMDF) InsuJet approved for use?
